^
    Back
    Association details:
    Biomarker:PIK3CA H1047R
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:pictilisib (GDC-0941) (PI3K inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    JAMA Otolaryngol Head Neck Surg
    Title:

    Response of Head and Neck Squamous Cell Carcinoma Cells Carrying PIK3CA Mutations to Select Targeted Therapies

    Excerpt:
    the hotspot E545K and H1047R mutations conferred decreased, rather than increased, sensitivity as measured by IC50 when treated with the respective HSP90, PI3K, and MEK inhibitors, 17-AAG, GDC-0941, and trametinib, compared to the SCC25 control cell lines....treatment with GDC-0941 also revealed a relative resistance in PI3K-mutant carrying cells.
    DOI:
    10.1001/jamaoto.2015.0471